SOD1 and amyotrophic lateral sclerosis: SOD1, central to familial ALS, has been effectively leveraged in genetic-targeted therapies such as Tofersen (ATLAS), with longitudinal measurements of mutant SOD1 allowing evaluation of therapy engagement and functional outcomes (Bensimon et al., 2025; Bowser et al., 2024; Miller et al., 2022).